Top Story
August 19, 2017
Tandem Diabetes Care has announced the enrollment of the first participant in an at-home trial assessing predictive low glucose suspend technology, according to a press release.
The trial will assess the safety and efficacy of Tandem’s t:slim X2 insulin pump with predictive low glucose suspend, which suspends insulin delivery when glucose gets to low and resumes delivery when glucose rises. The trial will also use Dexcom’s G5 mobile continuous glucose monitor as part of the delivery system.